Medicaid Managed Care Plan Clinical Criteria Worksheet: Zynteglo® (betibeglogene autotemcel)

Claim Submission

- Prior Authorization may be delayed if the information submitted in this worksheet is illegible.
- If the worksheet is left blank or information is missing the prior authorization will be rejected for not enough documentation.
- Once completed the worksheet will be sent via **SECUR**E email to <u>NYRX@health.ny.gov</u>

Medicaid Managed Care Plan Name

_											<u>. </u>										3		
Enr	olle	e li	nto	rma	atio	on																	
Enro	llee	Last	Nan	ne:							E	nroll	ee Fi	rst N	ame	:							
] [
Date	of B	irth	(MN	//DI	יץ/ס	YYY):				L L	nroll	ee M	ledic	aid I	D (2	let	ters,	5 nı	imbe	rs, 1	lette	er):
		/			1						Γ												
Add	ress:	L			J																		
City,	Tow	n or	Pos	t Of	fice	:										Stat	e:		ZIP	Cod	e:		
						T																	
Pre	scri	ber	· In	for	ma	tio	n																
				_			••							F :	New								
Pres	cribe	r Las	ST INA	ame	:	<u>r</u>				1		rescr	Iber	FIrst	Nar	ne:		1	1				1
Nati	onal	Prov	/ide	r Ide	ntif	ier((NPI)	Nur	nber	:													
Pref	erred	d Cor	ntac	t (Te	lep	hon	e Nu	mbe	er)														
			- [7 -																
Enro	llee	Last	Nan	ne:							E	nroll	ee Fi	rst N	ame	:							
Pha	arm	acy	Inf	or	na	tio	n																
Pha	macy	/ Na	me:								 Ph	one	num	ber:				- 1		_	1		1
Nati	onal	Prov	vide	r Ide	ntif	ier((NPI)	Nur	nber	•	 B	-					-	•	•	-	-	-	

Enro	ollee	Last	Nan	ne:					Enro	llee	First	Nam	e:				

Clinical Criteria – Drug Information

Provide the expected date of drug administration	(MM/DD,	/YYYY):
	• • •	

Criteria – Clinical

1. Has the patient been approved for the coverage of medical care associated with Zynteglo® therapy?

🗌 Yes	🗌 No
-------	------

2. Does the patient have a diagnosis of transfusion-dependent beta-thalassemia?

Transfusion-depended beta-thalassemia is defined as a history of at least 100 mL/kg/year of packed red blood cells (pRBC) in the two (2) years preceding administration of betibeglogene autotemcel or with greater than or equal to eight (8) transfusions of pRBCs per year in the two(2) years preceding administration of betibeglogene autotemcel.

🗌 Yes	🗌 N	0
-------	-----	---

3. Is the patient a candidate to undergo allogeneic hematopoietic cell transplantation, but ineligible due to the absence of a suitable donor?

Yes [No
-------	----

Enro	olle	ee l	.ast	Nar	ne:								E	Enro	llee	First	Nam	ne:							
	4.	ls ⁻	the	pati	ient l	ess t	han	or e	qual	to fi	fty (!	50) yo	ears	s of a	age?										
			Yes				No																		
	5.	ls ⁻	the	pati	ient l	ess t	han	five	(5) y	ears	of a	ge?													
			Yes				No																		
				If `	Yes,	does	the	patie	ent v	veigł	ı gre	ater	tha	n or	equa	al to :	six (6	5) kilo	ograr	ns?					
							Yes] No													
				(Z	ynte	glo® i	is no	t cov	vere	d for	pati	ents	less	s tha	n foi	ur (4)	yea	rs of	age	rega	rdles	s of v	weig	ht)	
	6.	ls	the	pati	ient o	on ar	ıy ar	nti-re	trov	iral r	nedi	icatio	ns?)											
			Yes	5			No																		
	7.	Ha		•												iteglo atien		r the	ir life	time)				
			Yes				No																		
	8.	ls ⁻	the	the	rapy	for a	me	dical	ly ac	cept	ed ir	ndica	tion	n and	d me	dicall	y ne	cess	ary?						
			Yes	i			No																		

Enrol	lee	Last	Nan	ne:					Enro	llee	First	Nam	e:				

Attestation

I attest that all of the information on this form is accurate to the best of my knowledge and is available for review if requested by the New York State Medicaid Program.

Managed Care Plan Representative

]								
Last	Nan	ne:								Fir	st Na	ame:	:				
Date	e (M	м/с] /	D/Y	YYY))] /												

Once completed the worksheet must be submitted via **SECUR**E email to <u>NYRX@health.ny.gov</u>

NOTE: A Medicaid Managed Care Plan representative should notify the NYRx program via SECURE email at <u>NYRx@health.ny.gov</u> once the target number of CD34+ cells have been collected for Zynteglo[®] manufacturing.